{"id":"ibudilast","rwe":[{"pmid":"41874311","year":"2026","title":"MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and are Clinically Relevant Across Central Nervous System Disorders.","finding":"","journal":"Cancer research","studyType":"Clinical Study"},{"pmid":"41839428","year":"2026","title":"Targeting autoimmunity: Phosphodiesterase inhibitors as immunomodulators-a review of current insights and future direction.","finding":"","journal":"Autoimmunity reviews","studyType":"Clinical Study"},{"pmid":"41754875","year":"2026","title":"Synergistic Enhancement of Peripheral Nerve Regeneration via Ibudilast-Primed Three-Dimensional Spheroid Culture of Human Adipose-Derived Stem Cells.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41753258","year":"2026","title":"Repurposed Systemic Pharmacologic Agents in Chronic Pain: Emerging Mechanistic and Clinical Insights.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"},{"pmid":"41664456","year":"2026","title":"Reductions in cigarette and cannabis use during a randomized clinical trial for alcohol use disorder.","finding":"","journal":"Alcohol and alcoholism (Oxford, Oxfordshire)","studyType":"Clinical Study"}],"tags":[{"label":"ibudilast","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A","category":"target"},{"label":"PDE4A","category":"gene"},{"label":"PDE4B","category":"gene"},{"label":"PDE4D","category":"gene"},{"label":"R03DC04","category":"atc"},{"label":"Active","category":"status"},{"label":"Asthma","category":"indication"},{"label":"Kyorin Pharmaceutical","category":"company"},{"label":"Anti-Asthmatic Agents","category":"pharmacology"},{"label":"Bronchodilator Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Phosphodiesterase Inhibitors","category":"pharmacology"},{"label":"Platelet Aggregation Inhibitors","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":324.634,"date":"","count":49,"signal":"Body tinea","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=325)"},{"llr":288.025,"date":"","count":49,"signal":"Infection susceptibility increased","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=288)"},{"llr":270.6,"date":"","count":47,"signal":"Inhibitory drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 47 times (LLR=271)"},{"llr":248.567,"date":"","count":49,"signal":"Glucose tolerance impaired","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=249)"},{"llr":244.059,"date":"","count":58,"signal":"Poor quality sleep","source":"DrugCentral FAERS","actionTaken":"Reported 58 times (LLR=244)"},{"llr":226.969,"date":"","count":51,"signal":"Impaired quality of life","source":"DrugCentral FAERS","actionTaken":"Reported 51 times (LLR=227)"},{"llr":221.819,"date":"","count":51,"signal":"Purpura","source":"DrugCentral FAERS","actionTaken":"Reported 51 times (LLR=222)"},{"llr":221.222,"date":"","count":49,"signal":"Bone density decreased","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=221)"},{"llr":205.168,"date":"","count":49,"signal":"Impaired work ability","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=205)"},{"llr":190.18,"date":"","count":49,"signal":"Hyperlipidaemia","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=190)"},{"llr":189.511,"date":"","count":49,"signal":"Oral herpes","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=190)"},{"llr":176.461,"date":"","count":49,"signal":"Skin disorder","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=176)"}],"commonSideEffects":[{"effect":"Emesis","drugRate":"","severity":"common","organSystem":""},{"effect":"Salivation","drugRate":"","severity":"common","organSystem":""},{"effect":"Vocalization","drugRate":"","severity":"common","organSystem":""},{"effect":"Erratic recovery","drugRate":"","severity":"common","organSystem":""},{"effect":"Prolonged recovery","drugRate":"","severity":"common","organSystem":""},{"effect":"Spastic jerking movements","drugRate":"","severity":"common","organSystem":""},{"effect":"Muscular tremors","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypertonicity","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspnea","drugRate":"","severity":"common","organSystem":""},{"effect":"Myoclonic jerking","drugRate":"","severity":"common","organSystem":""},{"effect":"Mild tonic convulsions","drugRate":"","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Respiratory depression","drugRate":"","severity":"serious"},{"effect":"Cyanosis","drugRate":"","severity":"serious"},{"effect":"Convulsions","drugRate":"","severity":"serious"},{"effect":"Opisthotonos","drugRate":"","severity":"serious"},{"effect":"Cardiac arrest","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"company":"Kyorin Pharmaceutical","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=IBUDILAST","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:20:20.126019+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:20:27.633137+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IBUDILAST","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:20:28.455878+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Phosphodiesterase 5A inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:20:29.044402+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL19449/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:20:28.935629+00:00"}},"allNames":"ketas","offLabel":[],"synonyms":["ketas","KP-305","ibudilast"],"timeline":[{"date":"1989-05-01","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Kyorin Pharmaceutical)"}],"approvals":[{"date":"1989-05-01","orphan":false,"company":"Kyorin Pharmaceutical","regulator":"PMDA"}],"brandName":"Ketas","ecosystem":[{"indication":"Asthma","otherDrugs":[{"name":"beclometasone dipropionate","slug":"beclometasone-dipropionate","company":""},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"}],"globalPrevalence":262000000}],"mechanism":{"target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A","targets":[{"gene":"PDE4A","source":"DrugCentral","target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A","protein":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A"},{"gene":"PDE4B","source":"DrugCentral","target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4B","protein":"cAMP-specific 3',5'-cyclic phosphodiesterase 4B"},{"gene":"PDE4D","source":"DrugCentral","target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4D","protein":"cAMP-specific 3',5'-cyclic phosphodiesterase 4D"},{"gene":"PDE4C","source":"DrugCentral","target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4C","protein":"cAMP-specific 3',5'-cyclic phosphodiesterase 4C"},{"gene":"MIF","source":"DrugCentral","target":"Macrophage migration inhibitory factor","protein":"Macrophage migration inhibitory factor"}],"modality":"Small Molecule","drugClass":"ibudilast","explanation":"","oneSentence":"","technicalDetail":"Ketas specifically targets cAMP-specific 3',5'-cyclic phosphodiesterase 4A (PDE4A), a phosphodiesterase enzyme responsible for the degradation of cAMP, thereby increasing intracellular cAMP levels and modulating cellular signaling pathways."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1406","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=IBUDILAST","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IBUDILAST","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:00:55.608948","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:20:30.821468+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"zafirlukast","drugSlug":"zafirlukast","fdaApproval":"1996-09-26","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"montelukast","drugSlug":"montelukast","fdaApproval":"1998-02-20","genericCount":30,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"ibudilast","indications":{"approved":[{"name":"Asthma","source":"DrugCentral","snomedId":195967001,"regulator":"FDA","usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"zafirlukast","brandName":"zafirlukast","genericName":"zafirlukast","approvalYear":"1996","relationship":"same-class"},{"drugId":"montelukast","brandName":"montelukast","genericName":"montelukast","approvalYear":"1998","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06743776","phase":"","title":"Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS","status":"AVAILABLE","sponsor":"Mayo Clinic","startDate":"","conditions":["ALS"],"enrollment":0,"completionDate":""},{"nctId":"NCT04057898","phase":"PHASE2,PHASE3","title":"Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS","status":"ACTIVE_NOT_RECRUITING","sponsor":"MediciNova","startDate":"2020-05-28","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":234,"completionDate":"2028-04"},{"nctId":"NCT05513560","phase":"PHASE2,PHASE3","title":"RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2023-05-31","conditions":["Long COVID","Post COVID Condition","Post Acute Sequelae of COVID-19"],"enrollment":460,"completionDate":"2025-12-31"},{"nctId":"NCT03341078","phase":"PHASE2","title":"Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2019-05-01","conditions":["Methamphetamine-dependence"],"enrollment":176,"completionDate":"2025-10-15"},{"nctId":"NCT03782415","phase":"PHASE1,PHASE2","title":"Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma","status":"COMPLETED","sponsor":"MediciNova","startDate":"2018-12-29","conditions":["Glioblastoma","Recurrent Glioblastoma","GBM","Newly Diagnosed Glioblastoma"],"enrollment":64,"completionDate":"2023-08-07"},{"nctId":"NCT05414240","phase":"PHASE2","title":"Ibudilast for Treating Alcohol Use Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-01-14","conditions":["Alcohol Use Disorder (AUD)","Alcoholism"],"enrollment":50,"completionDate":"2027-12-31"},{"nctId":"NCT03594435","phase":"PHASE2","title":"Ibudilast for the Treatment of Alcohol Use Disorder","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2018-10-01","conditions":["Alcohol Use Disorder"],"enrollment":102,"completionDate":"2023-04-19"},{"nctId":"NCT04429555","phase":"PHASE2","title":"Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS","status":"COMPLETED","sponsor":"MediciNova","startDate":"2021-01-11","conditions":["Pneumonia, Viral"],"enrollment":34,"completionDate":"2024-08-07"},{"nctId":"NCT02714036","phase":"PHASE1,PHASE2","title":"A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)","status":"COMPLETED","sponsor":"MediciNova","startDate":"2016-05-06","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":35,"completionDate":"2020-06-30"},{"nctId":"NCT01217970","phase":"PHASE1","title":"Safety Interaction Trial Ibudilast and Methamphetamine","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-01","conditions":["Methamphetamine-dependence","Substance Abuse"],"enrollment":11,"completionDate":"2013-03"},{"nctId":"NCT04631471","phase":"PHASE3","title":"Regeneration in Cervical Degenerative Myelopathy","status":"RECRUITING","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2021-12-22","conditions":["Myelopathy","Spinal Cord Diseases"],"enrollment":400,"completionDate":"2026-09-01"},{"nctId":"NCT02238626","phase":"PHASE2","title":"Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"MediciNova","startDate":"2014-09","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":70,"completionDate":"2017-12"},{"nctId":"NCT03489850","phase":"PHASE2","title":"Ibudilast and Withdrawal-Related Dysphoria","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2018-07-16","conditions":["Alcohol Use Disorder"],"enrollment":52,"completionDate":"2020-03-31"},{"nctId":"NCT01982942","phase":"PHASE2","title":"Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"MediciNova","startDate":"2013-11","conditions":["Multiple Sclerosis, Primary Progressive","Multiple Sclerosis, Secondary Progressive"],"enrollment":255,"completionDate":"2017-12"},{"nctId":"NCT04054206","phase":"PHASE1","title":"Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers","status":"COMPLETED","sponsor":"MediciNova","startDate":"2019-06-24","conditions":["Healthy Volunteers"],"enrollment":12,"completionDate":"2020-05-31"},{"nctId":"NCT03533387","phase":"PHASE1","title":"Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers","status":"COMPLETED","sponsor":"MediciNova","startDate":"2018-04-11","conditions":["Healthy Volunteers"],"enrollment":28,"completionDate":"2018-09-30"},{"nctId":"NCT01860807","phase":"PHASE2","title":"Trial of Ibudilast for Methamphetamine Dependence","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2013-07","conditions":["Methamphetamine Dependence","HIV Infection"],"enrollment":125,"completionDate":"2017-12-31"},{"nctId":"NCT01740414","phase":"PHASE2","title":"Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2012-11","conditions":["Opioid Abuse","Opioid Dependence"],"enrollment":28,"completionDate":"2017-05"},{"nctId":"NCT00723177","phase":"PHASE2","title":"Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-10","conditions":["Opioid-Related Disorders"],"enrollment":30,"completionDate":"2012-06"},{"nctId":"NCT02025998","phase":"PHASE1","title":"Development of Ibudilast for Alcohol Use Disorder","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2013-12","conditions":["Alcohol Use Disorders"],"enrollment":24,"completionDate":"2015-06"},{"nctId":"NCT01389193","phase":"PHASE1","title":"Ibudilast in the Treatment of Patients With Chronic Migraine.","status":"COMPLETED","sponsor":"Parisa Gazerani","startDate":"2013-06","conditions":["Migraine Headache"],"enrollment":33,"completionDate":"2015-12"},{"nctId":"NCT01317992","phase":"PHASE1,PHASE2","title":"Ibudilast in the Treatment of Medication Overuse Headache","status":"UNKNOWN","sponsor":"University of Adelaide","startDate":"2011-04","conditions":["Medication Overuse Headache"],"enrollment":40,"completionDate":"2013-08"},{"nctId":"NCT00576277","phase":"PHASE1,PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain","status":"COMPLETED","sponsor":"Avigen","startDate":"2006-09","conditions":["Diabetic Neuropathy"],"enrollment":36,"completionDate":"2007-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"010937","UNII":"M0TTH61XC5","CHEBI":"CHEBI:31684","INN_ID":"6068","UMLSCUI":"C0123047","chemblId":"CHEMBL19449","ChEMBL_ID":"CHEMBL19449","KEGG_DRUG":"D01385","DRUGBANK_ID":"DB05266","PDB_CHEM_ID":"AVL","PUBCHEM_CID":"3671","IUPHAR_LIGAND_ID":"7399","MESH_SUPPLEMENTAL_RECORD_UI":"C038366"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Kyorin Pharmaceutical","relationship":"Current Owner"}],"publicationCount":265,"therapeuticAreas":["Respiratory"],"atcClassification":{"source":"DrugCentral","atcCode":"R03DC04","allCodes":["R03DC04"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 24","pmid":"41874311","title":"MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and are Clinically Relevant Across Central Nervous System Disorders.","journal":"Cancer research"},{"date":"2026 Mar 14","pmid":"41839428","title":"Targeting autoimmunity: Phosphodiesterase inhibitors as immunomodulators-a review of current insights and future direction.","journal":"Autoimmunity reviews"},{"date":"2026 Feb 20","pmid":"41754875","title":"Synergistic Enhancement of Peripheral Nerve Regeneration via Ibudilast-Primed Three-Dimensional Spheroid Culture of Human Adipose-Derived Stem Cells.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2026 Feb 17","pmid":"41753258","title":"Repurposed Systemic Pharmacologic Agents in Chronic Pain: Emerging Mechanistic and Clinical Insights.","journal":"Journal of clinical medicine"},{"date":"2026 Jan 14","pmid":"41664456","title":"Reductions in cigarette and cannabis use during a randomized clinical trial for alcohol use disorder.","journal":"Alcohol and alcoholism (Oxford, Oxfordshire)"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Kyorin Pharmaceutical","companyId":"kyorin-pharmaceutical","modality":"Small molecule","firstApprovalDate":"1989","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"1989-05-01T00:00:00.000Z","mah":"Kyorin Pharmaceutical","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:20:30.821468+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}